Protein kinase CK2 is a serine/threonine protein kinase involved in various aspects of cellular regulation. The regulatory b-subunit of CK2 exerts a central role not only in mediating formation of tetrameric CK2 complexes but also as a docking partner for several protein kinases. In this study, CK2b is found to interact with the human cell cycle checkpoint kinase Chk1. The Chk1-interacting region of CK2b is localized at the C-terminus and the complex between CK2b and Chk1 is devoid of the catalytic CK2a-subunit. The interaction between CK2b and Chk1 leads to an increase in the Cdc25C phosphorylation activity of Chk1. The screening of several cell lines has revealed that the association between CK2b and Chk1 also occurs in vivo at a different degree. Collectively, these studies confirm the implication of the regulatory b-subunit of protein kinase CK2 in cell cycle regulation and identify a novel mechanism for the activation of Chk1 protein kinase.
Introduction
Protein kinase CK2, a serine/threonine kinase highly conserved through evolution, was first described almost 50 years ago (for a review see Pinna, 1990) . The enzyme has been found in lower eucaryotes such as Theileria parva and Dyctiostelium discoideum, in different groups of yeast, in plants and in the whole animal kingdom . CK2 is composed of two subunits, the catalytic a-subunit and the regulatory bsubunit. Recently, the crystal structure of the a-subunit (Niefind et al., 1998) and that of the holoenzyme (a 2 b 2 ) (Niefind et al., 2001 ) has been solved. The structure has suggested that the holoenzyme can dissociate into a dimer of the regulatory b-subunit and two molecules of the catalytic a-subunit. The C-terminal part of CK2b, the so-called CK2b tail, is involved in the interaction with the catalytic a-subunit (Niefind et al., 2001) .
Interestingly, an increasing number of studies have indicated that the CK2-subunits can interact with other cellular proteins . Thus, the CK2-subunits may have biological functions other than those assigned to the CK2 holoenzyme.
Several lines of evidences from different biological systems have suggested the involvement of CK2 in cell cycle regulation (for a review see . While CK2 holoenzyme appears to promote cell cycle progression, the regulatory b-subunit is implicated to participate in other pathways. It has been shown that CK2b can inhibit the activity of c-Mos preventing Xenopus oocytes maturation (Chen et al., 1997) . Moreover, the transient or the stable ectopic expression of Myc-tagged CK2b inhibits cell proliferation and reduces mitotic cyclin-dependent kinases activity (Li et al., 1999) . In S. cerevisiae, CK2b has been implicated in checkpoint regulation (Toczyski et al., 1997) . Specifically, this study has revealed that CK2b is required for the adaptation to G2 checkpoint, where yeast cells exit G2 arrest despite the persistence of DNA breakage.
An important regulator of DNA damage-induced G2 arrest is Chk1, a serine/threonine protein kinase that is conserved through evolution (Zhou and Elledge, 2000) . Chk1 was first identified in S. pombe as an essential protein kinase for G2 arrest induced by DNA damage (Walworth et al., 1993) . The mammalian Chk1, in addition to the activation of G2 checkpoint, is also required for the viability of embryonic stem cells (alKhodairy et al., 1994; Takai et al., 2000) . The activation of Chk1 kinase by DNA damage requires the ATR/ ATM family of protein kinases (Zhou and Elledge, 2000) . Activation of Chk1 is associated with its phosphorylation by the ATR/ATM family of kinases (Zhou and Elledge, 2000) . However, the precise mechanism for Chk1 kinase regulation has not been elucidated.
In this report, we describe the activation of Chk1 kinase by CK2b. We investigated the possible interaction between Chk1 and CK2b for two reasons. The first was the suggestion that CK2b has the potential to interact with the highly conserved N-lobe in the protein kinase domain; hence, CK2a may not be the sole interacting partner for the b-dimer. The second was the report that CK2b plays a role in the adaptation to G2 checkpoint in S. cerevisiae (Toczyski et al., 1997) . Our studies have demonstrated that CK2b indeed associates with Chk1 and can activate its kinase activity. The detection of a Chk1/CK2b complex in vivo supports the notion that CK2b play a role in the regulation of the cell cycle and identifies a novel mode of regulation of Chk1 kinase activity.
Results

Chk1 is a CK2b interacting partner
Increasing evidence has indicated that CK2b can interact with protein kinases other than CK2a. To explore the role of CK2b in the regulation of proteins that control cell cycle checkpoints, we have transiently expressed HA-tagged human Chk1 protein and MycHistagged human CK2b protein in Cos-1 cells (Figures 1  and 2 ). The expression of both the proteins was verified by Western blot of total cell lysates with monoclonal anti-HA and monoclonal anti-CK2b antibodies ( Figure 2a ). It is evident that when these two proteins are coexpressed, CK2b expression is increased ( Figure 2a , lane 4). Moreover, transfection with Chk1 alone leads to an increase of endogenous CK2b ( Figure 2a , lane 2). It is known that CK2b degradation is mediated by the proteosome (Zhang et al., 2002) . The fact that coexpression of CK2b with Chk1 leads to enhanced CK2b expression, might indicate a protective role of Chk1 with respect to CK2b degradation via the proteosome pathway.
To determine whether Chk1 associates with CK2b, immunoprecipitation experiments were performed using a polyclonal antibody directed against CK2b (Figure 2b ). The precipitated complexes were analysed on SDS-PAGE and probed with antibodies directed against CK2b, the Myc tag, CK2a and the HA tag. As expected, the immunoprecipitation of cell lysates with a polyclonal anti-CK2b antibody leads to the co-precipitation of CK2a ( Figure 2b, lanes 1-4) . Moreover, we found that CK2b coimmunoprecipitates with Chk1 ( Figure 2b lanes 2, 4) and that the endogenous CK2b interacts with the transfected HA-Chk1 ( Figure 2b , lane 2). Increased Chk1/CK2b complex could be detected with either anti-CK2b or anti-Myc antibodies when HAChk1 and CK2b-MycHis were coexpressed (Figure 2b , lane 4).
Chk1/CK2b complex is distinct from CK2a/CK2b complex Since both HA-Chk1 and CK2a were detected in antiCK2b immunoprecipitates, we wanted to determine whether HA-Chk1 associated with the CK2 holoenzyme or with CK2b alone. To achieve this goal, Cos-1 cells were transiently transfected with HA-Chk1 and either CK2a-MycHis or CK2b-MycHis plasmids (Figure 3a) . Cellular extracts were subjected to immunoprecipitation with a monoclonal antibody directed against Chk1. The precipitated complexes were analysed on SDS-PAGE and probed with a polyclonal anti-Myc antibody. As indicated in Figure 3a , CK2a-subunit is excluded from Chk1-Ck2b complex. Cellular extracts from Cos-1 cells, transiently transfected with HA-Chk1 and CK2b-MycHis plasmids, were fractionated on a Superdex 200 column. Fractions were collected, subjected to immunoprecipitation using polyclonal anti-CK2b antibody and the association with HA-Chk1 or CK2a was examined by immunoblotting ( Figure 3b ). The first seven fractions did not contain proteins, therefore the immunoprecipitation was performed from fractions 8 to 24 and coelution was detected from fractions 9 to 15. The elution of CK2 holoenzyme was detected in fractions 11-14. The elution profile of CK2 holoenzyme is distributed over a molecular mass range exceeding that expected for the tetrameric form of CK2. This result likely reflects, as already reported by several previous studies Grahm and Litchfield, 2000) , the fact that CK2, under physiological salt conditions, interacts with a variety of cellular proteins forming high molecular weight complexes. Importantly, the HA-Chk1 protein was not detected in fractions that contain CK2a and CK2b. Instead coelution of HA-Chk1 and CK2b was found in fractions 9 and 10. Moreover, CK2a is excluded from the complex containing HA-Chk1 and CK2b. The detection of CK2a in fraction 10 is the 'shoulder' of the eluted CK2a peak rather than a participation of CK2a in the CK2b-Chk1 complex formation. The native molecular weight of the Chk1-CK2b complex is much higher than that of the CK2 holoenzyme complexes (Figure 3b ). Although one would not necessarily expect the sedimentation value to be additive to the individual proteins, the data suggest that these proteins either multimerize, undergo conformational changes or bind to other so far unknown cellular proteins.
Interaction with Chk1 requires the C-terminal tail of CK2b
The crystal structure of human Chk1 kinase domain fragment in binary complex with the ATP analog AMP-PNP has been solved (Chen et al., 2000) . Based on this structure and that of the CK2 holoenzyme (Niefind et al., 2001) , we have used computer modeling to examine the possible interaction between Chk1 and CK2b. This analysis has revealed that the major contribution to the interaction with Chk1 is exerted by the C-terminal region, the so-called b tail of CK2b, which is characterized by a highly conserved sequence motif (K Niefind, personal communication) . To test this computer model, we have transfected Cos-1 cells with HA-tagged Chk1 and either a full-length CK2b-MycHis or a C-terminal-truncated mutant CK2b (1-155)-MycHis. The expression level of CK2b (1-155)-MycHis as well as of full-length CK2b-MycHis was analysed as indicated in Figure 4b , lanes 3 and 4. To examine the formation of CK2b-Chk1 complex, we incubated cell lysates with monoclonal anti-Chk1 antibody and then analysed the immunoprecipitates for the co-precipitation of CK2b-MycHis or CK2b(1-155)-MycHis. The anti-Chk1 antibody co-precipitated the full-length CK2b-MycHis as well as the endogenous CK2b ( Figure 4b , lanes 1 and 2) but not CK2b(1-155) (lane 2). Thus, deletion of 60 amino acids from the Cterminus abolishes CK2b-Chk1 complex formation. Despite the fact that polyclonal anti-HA antibody immunoprecipitates Chk1 (Figure 4a ), the attempt to precipitate the HA-Chk1/CK2b complex with anti-HA antibody was unsuccessful. According to the modeling, Chk1 is likely to interact with CK2b through its Nterminal lobe. It is conceivable that N-terminal HA tag might not be sufficiently exposed to react with anti-HA in the HA-Chk1/CK2b complex. Since the C-terminus of CK2b is required for its interaction with CK2a or Chk1, this is consistent with the exclusion of CK2a from the Chk1/CK2b complex.
CK2b enhances Chk1 kinase activity
To determine whether CK2b can modulate the kinase activity of Chk1, we performed immune-complex kinase assay using GST-Cdc25C 200-256 as a substrate. Previous studies have demonstrated that Chk1 phosphorylates serine 216 of Cdc25C (Peng et al., 1997) . Therefore, GST-Cdc25C 200-256 (S216A) was included as a negative control in the kinase assays described under 'Material and methods'. This experiment yielded two types of information. , and/or CK2b-MycHis plasmids (lanes 4 and 3, respectively) using pcDNA3.1 vector. Total lysates were subjected to SDS-PAGE, transferred to PVDF membrane and probed with monoclonal anti-CK2b, monoclonal anti-HA and monoclonal anti-tubulin antibodies. (b) Extract from transfected cells was subjected to immunoprecipitation using a polyclonal anti-CK2b antibody. Immunoprecipitates were analysed by Western blot probing the membrane with monoclonal anti-HA, monoclonal anti-Myc, monoclonal antiCK2a and monoclonal anti-CK2b antibodies. As control, cells were also transfected with pcDNA3.1 vector without insert (lane 1) and subjected to immunoprecipitation with polyclonal anti-CK2b antibody CK2 b-subunit modulates Chk1 kinase activity
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As expected, the ectopic expression of HA-Chk1 leads to increased Cdc25C phosphorylation in the anti-Chk1 immune complex (lane 2). Second, coexpression of HAChk1 with CK2b-MycHis caused the appearance of CK2b in the anti-Chk1 immune complex and a further increase in Cdc25C phosphorylation (lane 3). When the Cdc25C-Ser216A mutant was used, phosphorylation was abolished confirming the specificity of the Chk1 kinase activity (lane 4). To confirm the activation of Chk1 kinase in the Chk1/CK2b complex, we have compared Cdc25C phosphorylation in anti-HA versus anti-CK2b immune complexes (Figure 5b ). The phosphorylation of Cdc25C by HA-Chk1 in the anti-HA immune complex (lane 1) is lower than that observed by the HA-Chk1 in the anti-CK2b complex (lane 2). If we consider the amount of Chk1 co-precipitated with CK2b (lane 2) and that one precipitated with anti-HA antibody (lane 1), we can conclude that the CK2b-associated Chk1 form has considerable higher kinase activity.
Since the anti-CK2b immune complex contains CK2a (Figure 2b) , it was important to rule out that the phosphorylation of GST-Cdc25C was not due to the co-precipitated CK2a. We therefore performed the kinase assay in the presence of UCN-01 or heparin (Figure 5b , lanes 4 and 5). UCN-01 is a compound structurally related to staurosporine which inhibits several kinases (Graves et al., 2000) . As shown in Figure 5c , CK2 holoenzyme activity is not inhibited by 1 mm UCN-01. In contrast, phosphorylation of Cdc25C by the anti-CK2b immune complex was strongly inhibited by 1 mm UCN-01 (Figure 5b , lane 4). To further distinguish between the activity of Chk1 and CK2a, we used heparin which is a highly specific polyanionic inhibitor of CK2 (Hathaway et al., 1980) . As shown in Figure 5c , 80 ng/ml heparin inhibited CK2 holoenzyme activity by 80%. However, when added to the immune complex, in the kinase assay using Cdc25C as substrate, we found that the phosphorylation of Cdc25C was not inhibited by heparin at 80 ng/ml. (Figure 5b, lane 5) . Moreover, the anti-CK2b immune complex specifically phosphorylated Cdc25C at Ser216, because the kinase assay performed with GSTCdc25C 200-256 (S216A) mutant, as substrate, showed no incorporation of radioactive phosphate groups ( Figure 5 , lane 3). These experiments ruled out the contribution of CK2a-subunit to Cdc25C phosphorylation and supported the conclusion that Chk1 kinase activity towards Cdc25C is increased through its association with CK2b.
CK2b stimulates Chk1 kinase activity in vitro Figure 6a shows that recombinant Chk1 associates with recombinant CK2b confirming the in vivo results shown in Figure 2b . In order to answer the question if the stimulation of Chk1 kinase activity can be achieved by CK2b protein itself, we performed in vitro kinase assays with purified Chk1 (GST-Chk1) and CK2b proteins. As shown in Figure 6b , Chk1-catalyzed Cdc25C phosphorylation was enhanced by increasing the amounts of CK2b (i.e. from 0.3 up to 3 pmol) (lanes 2-6). When 1.8 pmol CK2b were added, Chk1-catalyzed Cdc25C phosphorylation increased twofold ( Figure 6b , lane 5; Figure 6c , bar 5) compared to the control experiment ( Figure 6b , lane 1; Figure 6c , bar 1). At a higher amount of CK2b, that is, 3 pmol ( Figure 6b , lanes 6; Figure 6c , bar 6) Cdc25C phosphorylation was increased up to 4.4-fold. A further increase of CK2b did not lead to a significant higher phosphate incorporation into Cdc25C substrate, suggesting that 1.8 pmol CK2b were sufficient to reach saturation under the conditions followed in the kinase assay. The addition of BSA, as shown in Figure 6c , bar 7, did not affect Cdc25C phosphorylation by Chk1. Moreover, kinase assays performed in the presence of approximately equal amounts of Cdc25C and CK2b, that is, 150 and 115 pmol, respectively, led to decreased phosphorylation of Cdc25C (results not shown). The data indicate that CK2b interacts with Chk1 also in vitro stimulating Chk1 kinase activity with respect to Cdc25C phosphorylation and suggest that CK2b could be a competitive substrate for Cdc25C.
Indeed, Figure 6d shows that Chk1 phosphorylates specifically CK2b (lane 3) and that CK2b acts as a competitive substrate with respect to Chk1-catalyzed Cdc25C phosphorylation (Figure 6d , lane 5).
CK2b associates with Chk1 in vivo
To investigate whether the putative Chk1 and CK2b association could be detected also in vivo, lysates of six different cell lines were subjected to immunoprecipitation with polyclonal anti-CK2b antibody (Figure 7a ). These immunoprecipitates were subjected to SDS-PAGE analysis and Western blot was probed with monoclonal anti-Chk1 and CK2b antibodies. The coimmunoprecipitation of Chk1 with CK2b was clearly detected in K562 and Y79 cell lysates (lanes 2 and 6). We estimated that between 3 and 5% of the total Chk1 could be co-precipitated with CK2b from these cell lysates. A weaker association between Chk1 and CK2b was detected in HCT116 cells and mouse 3T3 cells (lanes 4 and 5). The Chk1 signal in two other anti-CK2b immunoprecipitates (lanes 3 and 7) is comparable to the one in the control immunoprecipitation (lane 1). Western blot analysis of crude extracts of the six cell lines revealed the pattern of expression of Chk1 and CK2b to be comparable (Figure 7b ), indicating that the complex formation may be regulated by factors other than the amount of Chk1 and CK2b present in the cells. To examine if the CK2b-Chk1 complex formation is indeed regulated during checkpoint responses, K562 cells were treated with etoposide and immediately thereafter the CK2b-Chk1 complex was immunoprecipitated and analysed by Western blot. As shown in Figure 7c , the level of CK2b-Chk1 complex remains unchanged upon treatment with etoposide. The same result was obtained when K562 cells were treated with 12 Gy g-IR and harvested at different time points (data not shown). The kinase activity of Chk1 in complex with CK2b has been tested before and after treatment with etoposide or 12 Gy g-IR and no increase of CDC25C phosphorylation has been observed after cell treatment (results not shown).
Discussion
Protein kinase CK2 is a serine/threonine kinase highly conserved in eucaryotic cells. It is a general opinion that CK2 exists in vivo mainly as a holoenzyme composed of two catalytic subunits (a and/or a 0 ) and two regulatory b-subunits. Several evidences indicate that the isolated subunits can exist in vivo (Pinna and Meggio, 1997; . The crystal structure of the CK2 holoenzyme (Niefind et al., 2001) has shown that the a/b interface is relatively small. The structure supports the notion that the CK2 holoenzyme may be a transient heterocomplex and reinforces the idea that CK2-subunits might have independent cellular functions.
The results presented in this paper demonstrate that the regulatory CK2b-subunit interacts specifically with Chk1 and that the complex formation takes place in the absence of catalytic CK2-subunits. Previous studies have indicated the interaction of CK2b with protein kinases including A-Raf, c-Mos, p90 rsk (for a review see and, more recently, PKCz (Diaz-Meco et al., 1994; Bren et al., 2000) . Our data have extended the list to include Chk1 as another partner of CK2b. We have shown that the C-terminal region of CK2b is important for Chk1 binding. The deletion of 60 amino acids from the C-terminus of CK2b abolishes the capability of CK2b to interact with the catalytic a-subunit (Boldyreff et al., 1993) . It is possible that the C-terminus of CK2b recognizes a common structural motif of serine/threonine kinases. However, the fact that CK2b interacts specifically with A-Raf (Boldyreff and Issinger, 1997) but not c-Raf (Chen et al., 1997; Hagemann et al., 1997) , suggests that kinase interaction with CK2b may require higher specificity. The structure determination of the human Chk1 kinase (Chen et al., 2000) has indicated that the activity of the kinase domain (residues 1-265) of human Chk1 is over 20-fold more active than the full-length Chk1 kinase toward Cdc25C substrate. These data support the idea that the C-terminal region of Chk1 plays a negative role on Chk1 kinase activity. It is conceivable that the interaction of CK2b with Chk1 might counteract such an autoinhibition mechanism to enhance the Chk1 kinase activity.
An earlier genetic study in S. cerevisiae has implicated CK2b in checkpoint regulation (Toczyski et al., 1997) . Specifically, that study found that the regulatory b-subunit of CK2 is required for adaptation, which describes a process where yeast cells recover from the G2 checkpoint and resume proliferation despite the continued presence of DNA damage. It is interesting to note that the CK2a genes (CKA1/CKA2) were not isolated in that genetic screen for adaptation defects (Toczyski et al., 1997) . Thus, only CK2b, instead of the CK2 holoenzyme might be involved in the checkpoint adaptation. In S. cerevisiae, G2/M arrest in response to DNA damage is coordinately regulated by the RAD53 and Chk1 kinase (Sanchez et al., 1999) . Adaptation to G2/M checkpoint has been correlated with the dephosphorylation of RAD53 and Chk1 (Pelliccioli et al., 2001 ). It would be of interest to The constitutively present Chk1-CK2b complex may mediate the basal phosphorylation of Cdc25C or other Chk1 substrates during normal cell cycle progression. Indeed, Cdc25C is phosphorylated on Ser216 in normal S phase cells in the absence of genotoxic stress (Peng et al., 1997) . Moreover, Chk1 is essential for normal cell cycle progression because Chk1 knockout causes lethality of ES cells (Liu et al., 2000; Takai et al., 2000) . The basal activity of Chk1 might depend on its association with CK2b, whereas the increased activity of Chk1 following genotoxic stress (Liu et al., 2000; Zhao and Piwnica-Worms, 2001 ) is mediated by the ATR/ATM family of protein kinases. Indeed, the fact that under checkpoint activation we did not observe any change in the CK2b-Chk1 complex supports the notion that CK2b might contribute in the maintenance of the basal activity of Chk1.
In summary, this study has shown that the regulatory b-subunit of protein kinase CK2 binds to and activates Chk1 protein kinase with respect to Cdc25C phosphorylation. Our in vitro results suggest that CK2b can directly enhance Chk1 kinase activity, although we cannot exclude the involvement of other proteins in the Chk1-CK2b complex to also play a role in modulating Chk1 kinase activity. The functional interaction between Chk1 and CK2b provides important insight into how CK2 function is linked to cell cycle regulation and it is consistent with the genetic evidence implicating CK2b in cell cycle checkpoint. Further investigations to identify signals and pathways that control the interaction between Chk1 and CK2b may provide more insights on the biological functions of Chk1 and CK2.
Materials and methods
Chemicals and reagents
7-Hydroxystaurosporine (UCN-01) was provided by Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NIH, while heparin was obtained from Sigma.
Plasmid constructs
Human HA-tagged Chk1 plasmid was kindly provided by Clare McGowan (San Diego, CA, USA). (S216A) plasmids were kindly provided by Stephen J Elledge (Houston, TX, USA).
Full-length CK2b containing C-terminal MycHis epitope tag (CK2b-MycHis) was expressed using pcDNA3.1 vector (Invitrogen). A BamHI/HindIII and BamHI sites were (antisense primer). The amplified sequence was subcloned into pcDNA3.1 vector. The correct sequence and orientation were verified by DNA sequencing. A construct encoding full-length CK2b without C-terminal tag was generated digesting CK2b-MycHis with HindIII and BamHI. After gel purification, the fragment was ligated into the HindIII/BamHI sites of the pcDNAZeo( þ ) vector (Invitrogen). The construct was verified by restriction endonuclease digests. The constructs encoding a deletion mutant of CK2b, designated CK2b(1-155)-MycHis, were generated from fulllength CK2b using: 5 0 -CGGGATCCAAGCTTATGAG-CAGCTCAGAGGAGGTG-3 0 (sense primer) and 5 0 -GAGGGGATCCTCAGGGCCGGTACTCGGGATG-3 0 (antisense primer) to introduce a stop codon followed by a BamHI site. The construct was subcloned into pcDNA3.1 vector (Invitrogen) as HindIII/BamHI fragment and verified by DNA sequencing. Full-length CK2a containing C-terminal MycHis epitope tag (CK2a-MycHis) was cloned into pcDNA3.1 vector as described above with forward primer 5 0 -CGGGATC-CAAGCTTATGTCGGGACCCGTGCCAAGC-3 0 and reverse primer 5 0 -CGGGATCCGACTGCTGAGCGCCAGCGGCA-GC-3 0 .
Cell culture and treatments
Cos-1, 3T3, U2-OS and HCT116 3(6) cell lines were grown in Dulbecco's modified Eagles' medium (Irvine Scientific) supplemented with 10% fetal bovine serum (FBS) and 1 mm lglutamine. All cells were cultured at 371C with 5% CO 2 . K562 and Y79 cell lines were cultured in Roswell Park Memorial Institute medium (RPMI, Irvine Scientific) supplemented with 10% FBS and 2 mm l-glutamine. Cells were transfected using FuGene 6 reagent (Roche) with a total of 4 mg of DNA and 12 ml of transfection reagent in a total final volume of 200 ml serum-free medium using the manufacturer's recommendations. After 48 h, cells were harvested or treated as indicated in the figure legends.
Antibodies
HA-Chk1 was detected with mouse monoclonal anti-Chk1 antibody (clone 34) purchased from BD Transduction Laboratories, mouse monoclonal anti-HA (HA.11, Covance) antibody or rabbit polyclonal anti-HA (Y-11, Santa Cruz) antibody. Recombinant and native CK2b were detected with mouse monoclonal (6D5) anti-CK2b antibody (Calbiochem) or mouse monoclonal anti-Myc (Ab-1) antibody (Oncogene) or a rabbit polyclonal anti-CK2b antibody obtained immunizing rabbits against the native protein. CK2a was detected with mouse monoclonal antibody (1AD9) purchased from Calbiochem. Tubulin was detected with a monoclonal anti-a-tubulin antibody (B-5-1-2) from Sigma. Protein-antibody complexes were visualized by a chemiluminescence Western blotting detection system according to the manufacturer's specifications (CDP-Star, Applied Biosystems).
Preparation of cell extract
Cell extract was prepared as previously described and used for SDS-PAGE, Western blot analysis, protein kinase assay or immunoprecipitation experiments.
Purification of recombinant human CK2b
The wild-type form of CK2b was expressed in Escherichia coli as described previously (Boldyreff et al., 1993) . Bacteria pellets were resuspended in buffer A (50 mm Tris-HCl pH 8.5, 1 mm DTT, protease inhibitors cocktail-Complete, Roche) containing 100 mm NaCl. Bacteria were disrupted by sonication and subsequently centrifuged for 30 min at 10 000 g. Protein extraction from the pellet was performed on ice by gentle stirring overnight in buffer A containing 1 m NaCl. The protein extract was centrifuged as indicated above and the supernatant was extensively dialyzed against buffer B (50 mm Tris-HCl pH 8.5, 1 mm DTT) containing 300 mm NaCl. The supernatant was subsequently loaded onto Resource Q (Amersham-Biosciences) and the proteins were eluted with a linear gradient from 300 mm to 1 m NaCl in buffer B. The purest fractions were collected and dialyzed in buffer B containing 300 mm NaCl. Aliquots were stored at À701C until further usage. GST-Cdc25C 200-256 and GST-Cdc25C 200-256 (S216A), the latter contains a mutation in the target serine phosphorylated by Chk1, were expressed in bacteria and purified resuspending the bacteria pellet in lysis buffer containing 50 mm Tris-HCl pH 7.4, 300 mm NaCl and a protease inhibitors cocktail (Complete, Roche). Disruption of the bacteria by sonication was followed by centrifugation at 41C for 30 min at 10 000 g. The collected supernatant was loaded onto GSH-agarose (Amersham-Biosciences). After extensive washing, proteins were eluted in buffer containing 50 mm Tris-HCl pH 8, 10 mm reduced glutathione. The eluted proteins were extensively dialyzed in buffer containing 50 mm Tris-HCl pH 8, 1 mm DTT, 300 mm NaCl and 50% glycerol and stored in aliquots at À701C.
Protein kinase assays
CK2 activity was performed as described previously , while Chk1 kinase assay was performed, after immunoprecipitation of the enzyme, in kinase buffer (50 mm Tris-HCl pH 7.4, 1 mm DTT, 10 mm MgCl 2 , 50 mm ATP, 10 mCi of [g-32 P]ATP, 100 mm sodium orthovanadate) and 5 mg of . Reaction mixtures (60 ml) were incubated at 301C for 25 min and analysed by SDS-PAGE after addition of SDS sample buffer. Proteins were transferred to PVDF membrane. Radiolabeled proteins were visualized by autoradiography. The same membranes were subsequently probed with different antibodies as indicated in the figure legends. In vitro kinase assay with recombinant Chk1 (Upstate Biotechnology) was performed following the manufacturer's instructions using, as substrates, either GSTCdc25C 200-256 or recombinant CK2b. The radioactivity incorporated into the substrate targets was determined by scintillation counting (Hewlett-Packard) of the excised radioactive bands.
Immunoprecipitation
Immunoprecipitation was performed essentially as described previously with either monoclonal antiChk1 antibody (G-4, Santa Cruz), rabbit polyclonal antiCK2b serum or rabbit polyclonal anti HA antibody (Santa Cruz). 
Chromatographic analysis of Chk1-CK2 complex formation
Crude extract (1 mg) from Cos-1 cells cotransfected with HAChk1 and CK2b plasmids was analysed by analytical gel filtration chromatography using a Superdex 200 column PC 3.2/30. (SMART System Amersham-Biosciences) equilibrated in buffer containing 25 mm Tris-HCl pH 8.5, 1 mm DTT and 300 mm NaCl. After chromatography, fractions with significant absorbance were subjected to immunoprecipitation with rabbit polyclonal anti-CK2b serum. The immunoprecipitates were subjected to Western blot and the membrane was incubated with mouse monoclonal anti-HA, anti-CK2a and anti-CK2b antibodies for revealing the elution pattern of CK2b interacting proteins.
